HighVista Strategies LLC Sells 11,415 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

HighVista Strategies LLC decreased its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 9.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 115,326 shares of the company’s stock after selling 11,415 shares during the quarter. HighVista Strategies LLC’s holdings in Roivant Sciences were worth $1,331,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of ROIV. nVerses Capital LLC acquired a new position in Roivant Sciences during the 2nd quarter worth $34,000. Gladius Capital Management LP acquired a new position in Roivant Sciences during the 3rd quarter worth $35,000. Point72 Hong Kong Ltd acquired a new position in Roivant Sciences during the 2nd quarter worth $36,000. US Bancorp DE lifted its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares in the last quarter. Finally, Quarry LP acquired a new position in Roivant Sciences during the 2nd quarter worth $53,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on ROIV. Bank of America upped their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Stock Down 1.8 %

ROIV opened at $12.48 on Tuesday. Roivant Sciences Ltd. has a 12 month low of $9.48 and a 12 month high of $13.06. The company has a fifty day simple moving average of $11.77 and a 200 day simple moving average of $11.38. The stock has a market cap of $9.08 billion, a P/E ratio of 2.21 and a beta of 1.25.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares in the company, valued at approximately $6,865,863. This represents a 14.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Matthew Gline sold 1,983,257 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $11.79, for a total value of $23,382,600.03. Following the transaction, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at approximately $210,693,701.97. This trade represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,677,309 shares of company stock worth $43,283,184 in the last quarter. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.